National Institutes of Health (NIH):
Innovative technologies and methodologies fuel progress in biomedical and behavioral research and represent an increasingly important area of the economy. The Small Business Innovation Research (SBIR) program provides support for research and development (R&D) of new or improved technologies and methodologies that have the potential to succeed as commercial products.
PHASE I: The objective of this phase is to determine the scientific and technical merit and feasibility and potential for commercialization of the proposed research or R&D efforts and the quality of performance of the small business concern, before consideration of further Federal support in Phase II. Generally, Phase I SBIR awards do not exceed $150,000 for direct costs, Facilities and Administrative (F&A) costs, and negotiated fixed fee for a period generally not to exceed six months.
PHASE II: The objective of this phase is to continue the research or R&D efforts initiated in Phase I. Funding shall be based on the results of Phase I and the scientific and technical merit and commercial potential of the Phase II proposal. Phase I contractors are eligible to apply for Phase II grant or contract funding and will be informed of Phase II opportunities. (However, see “Fast-Track” Initiative and “Direct to Phase II” below.) Generally, Phase II awards do not exceed $1,000,000 for direct costs, F&A costs, and negotiated fixed fee for a period generally not to exceed two years.
- Due date: October 23, 2019
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.
- Awards: Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Award Project Period: The R61 phase can be from 1-3 years and the R33 phase can be 1-2 years, with a total project duration of no more than 5 years.
- Due Dates: September 4, 2019; February 14, 2020; July 20, 2020; February 17, 2021; July 19, 2021; and February 14, 2022. Letter of intent due 30 days prior to application due date.
The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.
Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins.
The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base.
- Awards: Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year.
- Due Dates: Letters of intent due September 28, 2019; applications due October 28, 2019.
Limited Submission Opportunities (https://vpr.tamu.edu/initiate-research/lsp):
|Program Name||Declaration of Intent Due
|NSF: Critical-Zone Collaborative Network||09/04/2019||09/11/2019||12/02/2019|
|NSF: Advancing Informal STEM Learning||08/08/2019||08/15/2019||11/06/2019|
|NSF Advanced Computing Systems & Services: Adapting to the Rapid Evolution of Science and Engineering Research||08/08/2019||08/15/2019||11/05/2019|
|NIH Occupational Safety and Health Training Project Grants||7/26/2019|
|NIH Nutrition Obesity Research Centers||7/22/2019|
… Our values have not changed. What has changed is the scope and sophistication of the activities threatening our research community, such as certain foreign-government-sponsored talent recruitment programs. These activities create new risks to the integrity of NSF’s mission and operation. NSF is therefore taking multiple steps to mitigate these risks in concert with other agencies and stakeholders, as outlined below…. (click link above for full letter)
The intent of this notice is to remind the extramural community about the need to report foreign activities through documentation of other support, foreign components, and financial conflict of interest to prevent scientific, budgetary, or commitment overlap. NIH has long required full transparency for all research activities both domestic and foreign and does not consider these clarifications to be changes in policy. The requirements referenced in this Notice, along with the other obligations in the NIH Grants Policy Statement (NIHGPS) and other terms and conditions of award, are instrumental to achieving the mutual goal of NIH and the extramural community, to protect the integrity of biomedical research…. (click link above for full notice)
It is a priority to us to continue to engage with the community about what constitutes a breach of NIH peer review integrity – including, but not limited to:
- A reviewer sending grant applications to their postdocs to write their critiques
- Someone revealing that they reviewed a particular application
- A reviewer disclosing how another reviewer scored an application
- A principal investigator (PI) approaching a reviewer at a scientific conference to discuss her/his institution’s application in which s/he is designated as PI
Yes, each of these constitutes a breach of NIH peer review integrity…. (click link above for full article)